Deal-Making in the Current Environment: A Fireside Chat with Alban de La Sablière, Head of Partnering, Sanofi

12:15 PM - 1:30 PM (PDT), Wednesday, June 15, 2022

Since November 2019, Alban de La Sablière has been SVP Global Head of Partnering, that includes the Sanofi Ventures Fund, Business Development & Licensing and Alliance Management. Previously SVP Head of Business Development & Licensing, over the last two years, he has overseen repositioning of the Business Development activities in line with Sanofi strategy, including partnership deals with Biond Biologics, C4X, Eureka Therapeutics, Abl-Bio, Seagen, Blackstone and IGM Biosciences, and multiple ventures investments including Muna Therapeutics, Rome Therapeutics, Recode Therapeutics, Normunity and Omass Therapeutics. Alban joined Sanofi in January 2016 as SVP, Head of Mergers & Acquisition where he led the Bioverativ, Ablynx and Protein Sciences acquisitions, and portfolio-reshaping divestments including the sale of Zentiva. Prior to joining Sanofi, Alban worked for Morgan Stanley, where he worked with Sanofi on deals, including the merger of Sanofi & Aventis and the Genzyme acquisition.

Sponsored By
Managing Editor
Scrip Intelligence
Global Head of Partnering